1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Britannia Life Sciences Inc.

Britannia Life Sciences Inc.

BLAB.CN
Britannia Life Sciences Inc.CA flagCanadian Securities Exchange
0.07
CAD
- -
- -
11.36MMarket Cap
Britannia Life Sciences Inc.
BLAB.CN
(Canadian Securities Exchange)

Recent

price

0.07

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
FRC
0.02
0.07
0.04
- -
- -
-0.03
Revenue per Share
- -
-0.14
0.03
-0.03
0.05
0.13
Basic EPS, GAAP
-0.01
0.02
0.01
0.01
-0.02
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
0.01
0.03
- -
0.02
0.09
Book Value per Share
-0.2
-0.11
-0.04
-0.07
0.04
0.11
Tangible Book Value per Share
78
110
162
162
162
162
Basic Weighted Avg Shares
1
7
6
1
- -
-4
Sales/Revenue/Turnover
19.83
-114.47
15.52
-1,320.32
-548.2
82.58
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-15
5
-5
7
20
Net Income, GAAP
64.31
- -
0.34
- -
- -
17.39
Effective Tax Rate (%)
-11.03
-211.76
79.39
-922.51
2,001.95
-472.89
Profit Margin (%)
-8
-5
- -
-8
6
12
Working Capital
3
- -
6
5
2
- -
LT Debt
3
5
11
7
6
17
Total Equity
- -
- -
6.57
- -
- -
-19.43
Return on Invested Capital (%)
- -
- -
37.26
- -
- -
163.09
Return on Capital (%)
- -
- -
168.44
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
ST Debt
- -
- -
- -
LT Borrowings
2
2
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
162
162
162
Market Capitalization
10
14
15

Working Capital

FRC

•

in mil. unless spec.
Jun'26
Sep'26
Dec'26
Total Current Assets
8
3
17
Cash, Cash Equivalents & STI
6
1
16
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
3
3
5
Payables & Accruals
2
3
5
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-5.54%
Free Cash Flow
- -
- -
-249.33%
Net Income, GAAP
- -
- -
-255.06%
Sales/Revenue/Turnover
- -
- -
-28.55%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2
2
2
2
1
2025
- -
- -
- -
-5
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-0.03
2025
- -
-0.01
- -
- -
0.05
2026
- -
- -
0.07
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nicox S.A. (NICXF)
Intercept Pharmaceuticals, Inc. (ICPT)
Celularity Inc. (CELU)
Jiangsu Recbio Technology Co., Ltd. (2179.HK)
Minerva Neurosciences, Inc. (NERV)
Aprea Therapeutics, Inc. (APRE)
Business
Britannia Life Sciences Inc. Britannia Life Sciences Inc. (CSE:BLAB) operates as a diversified services platform providing laboratory support, product development, testing, safety assessment, analytical and microbiological services, global compliance, and consumer evaluations primarily to clients in the cosmetics, consumer packaged goods, food and beverage, nutraceutical, household goods, and wellness industries; it offers specialized expertise in topical and edible cannabis products including novel food authorizations, as well as geochemical testing and PhotonAssay technology through its subsidiary Britannia Mining Solutions Inc. for the natural resources sector. The company maintains an ISO 17025 accredited laboratory and serves multinational corporations, retailers, brands, and startups across North America, Europe, the United Kingdom, and international markets, with headquarters in Toronto, Ontario, Canada. Founded through a 2021 reverse takeover and historically focused on science-based services, Britannia Life Sciences recently divests its UK laboratory and testing business to a private acquiror for up to CAD$43.6 million in enterprise value and enters a $11.3 million share exchange agreement with McEwen Inc. and Britannia Mining Solutions Inc. (dba Paragon Geochemical Laboratories Inc.), crystallizing value in its mining analytical services portfolio while repositioning toward private debt, non-resource royalties, and potential rebranding beyond life sciences.

Company News

APIChatGPT